Breye Completes Phase 1b Trial of Danegaptide for Retinopathy
June 24, 2025
Orally administered treatment was well tolerated, with early signs of clinical activity Breye Therapeutics, a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the